Educational only. Not medical advice.
Peptides have been moving through Washington quickly. As of October 24, 2026, the most important development is this: FDA and HHS sent an interim access policy for compounding certain peptides to the White House Office of Management and Budget on October 14. As of mid-October it was still under review, and its text has not been published.
That is a real step. It is also not a finish line. Here is a plain-English timeline of what has happened and what has not.
The timeline
July 23–24: FDA's advisory committee votes
FDA's Pharmacy Compounding Advisory Committee met for two days to consider whether certain peptides could be added to the 503A Bulks List, which governs what pharmacies may compound. FDA's own staff recommended against all seven substances. They said the available studies were short, small and not enough to establish safety or effectiveness for the proposed uses.
The committee voted differently on six of the seven:
- BPC-157, KPV and TB-500: each passed 8–6, with one abstention.
- MOTS-c: passed 7–5, with two abstentions.
- Semax and Epitalon: cleared by similarly narrow margins.
- Emideltide: did not pass (7–6, one abstention).
These votes are advisory and nonbinding. FDA is not required to follow them, and none of these peptides has been added to the list.
October 14: an interim policy goes to the White House
The interim policy is expected to describe when certain peptides could temporarily be compounded while FDA works through the formal process. Which peptides it covers, and under what conditions, has not been made public. Legal commentators note that a policy like this would most likely signal enforcement discretion, not a change in law and not an FDA approval.
October 22: reporting rules in the headlines
Bloomberg ran a story headlined that the broader plan would make compounders report side effects. We have not seen the details, so we are not going to characterize them. We will update this article when the specifics are public.
February 2027: the next meeting
The advisory committee is scheduled to take up five more substances: cathelicidin, GHK-Cu, dihexa acetate, melanotan II and PEG-MGF.
What this does and does not mean
- Eligible for compounding is not FDA approval. It does not mean FDA has found a peptide safe and effective for any use.
- Nothing changes overnight. A final outcome still runs through a proposed rule, public comment and a final rule. The interim policy has no published effective date.
- State rules still apply. Pharmacy boards and FDA's existing 503A requirements, including ingredient sourcing and quality documentation, remain in force.
- Insurance is unlikely to change. Compounded drugs generally fall outside standard pharmacy benefits, so patients would likely keep paying out of pocket.
- Athletes, take note. BPC-157 and TB-500 are classified as prohibited substances by international anti-doping authorities, regardless of FDA's decision.
Why the source matters more than the headline
When rules loosen, attention rises, and so does the number of sellers. The question for anyone considering a peptide has not changed: is it prescribed by a licensed clinician, prepared by a licensed pharmacy, and documented? Research-use-only products are not a substitute for that.
At filled. HEALTH, prescription peptides are dispensed through a licensed US pharmacy after clinician review. We do not make treatment claims about these products, and we will not describe anything pending as approved.
What to watch next
- Whether the interim policy is published, and which substances it names.
- Any details on side-effect reporting for compounders.
- FDA's formal response to the July committee votes.
- The February 2027 committee agenda.
Sources: reporting from AJMC (July 31, 2026), Bergeson & Campbell (October 2026), GoodRx's regulatory tracker (reviewed October 16, 2026) and Bloomberg (headline, October 22, 2026). This article is for education and is not medical or legal advice. Prescription required for all Rx products.
0 comments